Joel Lewis - 16 Jan 2026 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Reporting relationship: President and CEO, Director
Issuer ticker: GALT
Reported as of: 16 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jan 2026, 16:48:29 UTC
Prior SEC filing: 13 Jan 2026
Source filing: View source filing
Reporting owner signature: Jack W. Callicutt

Key filing fact

Joel Lewis filed Form 4 for GALECTIN THERAPEUTICS INC (GALT) on 21 Jan 2026.

Key facts

This page summarizes Joel Lewis's Form 4 filing for GALECTIN THERAPEUTICS INC (GALT).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 21 Jan 2026, 16:48.

Change

Previous filing in this sequence was filed on 13 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001725595 Primary reporting owner

LEWIS JOEL

Relationship: President and CEO, Director
Address: C/O GALECTIN THERAPEUTICS INC., 4960 PEACHTREE INDUSTRIAL BLVD., STE 240, NORCROSS
Signature: Jack W. Callicutt
Signature date: 21 Jan 2026

This filing has been restated. Open the amended filing.

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GALT transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +84,000
Change %
Price: $0.000000
Shares after: 65,000
Date: 16 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 84,000
Exercise price: $3.04
Footnotes: F1, F2

GALT transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +120,000
Change %
Price: $0.000000
Shares after: 100,000
Date: 16 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 120,000
Exercise price
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

Footnote F2

The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027.

Footnote F3

Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement.

Footnote F4

The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.